---
title: "Phase III Randomized Trial of IO-Based Systemic Treatment +/- Liver SBRT in Hepatocellular Cancer With Macrovascular Invasion (HELIO-RT)"
canonical: "https://www.renown.org/clinical-trials-directory/NCT07166406"
last_updated: "2026-09-22T22:08:26Z"
---

# Phase III Randomized Trial of IO-Based Systemic Treatment +/- Liver SBRT in Hepatocellular Cancer With Macrovascular Invasion (HELIO-RT)

URL: https://www.renown.org/clinical-trials-directory/NCT07166406

Short Title: NRG-GI012

Enrollment Status: Recruiting

NCT #: [NCT07166406](https://clinicaltrials.gov/study/NCT07166406)

Specialty Area: Oncology

Condition Studied: Hepatocellular Carcinoma

Age Groups: Adult; Older Adult

Sex: All

Study Type: Interventional

Accepts Healthy Volunteers: No

Phase: III

Principal Investigator: Garrett Green, MD

Complete Study Details: https://clinicaltrials.gov/study/NCT07166406

## Study Information

### Summary / Purpose

The purpose of this study is to compare the usual treatment of immunotherapy-based drug treatment alone to using liver stereotactic body radiation therapy (SBRT) plus the usual treatment.

### Who Can Participate

- Adults 18+ years of age
- Diagnosis of hepatocellular carcinoma (HCC)
- HCC macrovascular invasion
- Cannot be pregnant or nursing
- No prior systemic therapy or transarterial radioembolization

### What's Involved

- Random assignment to receive immunotherapy alone or immunotherapy combined with stereotactic body radiation therapy (SBRT) to the liver
- Receiving immunotherapy medications by intravenous (IV) infusion as determined by the study treatment plan
- Computed tomography (CT) scan
- Magnetic resonance imaging (MRI)
- Fludeoxyglucose (FDG) positron emission tomography (PET) scan
- Blood sample collection

## Additional Information

Location: Renown Health, Office of Clinical Research

Address: 1500 E 2nd St. Reno, NV 89502

General Research: [775-982-3646](tel:775-982-3646)

Oncology Research: [775-982-5050](tel:775-982-5050)

Email: [Renown-CRD@renown.org](mailto:Renown-CRD@renown.org)
